Elizabeth S Ver Hoeve1, Leila Ali-Akbarian2, Sarah N Price3, Nurhyikmah M Lothfi3, Heidi A Hamann4. 1. Department of Psychology, University of Arizona, 1503 E University Blvd., Tucson, AZ, USA. everhoeve@email.arizona.edu. 2. University of Arizona Cancer Center, 3838 N Campbell Ave., Tucson, AZ, USA. 3. Department of Psychology, University of Arizona, 1503 E University Blvd., Tucson, AZ, USA. 4. Departments of Psychology and Family and Community Medicine, University of Arizona, 1503 E University Blvd., Tucson, AZ, USA.
Abstract
PURPOSE: Fighting cancer is a costly battle, and understanding the relationship between patient-reported financial toxicity (FT) and health outcomes can help inform interventions for post-treatment cancer survivors. METHODS: Stages I-III solid tumor, insured US cancer survivors (N = 103) completed a survey addressing FT (as measured by the standardized COST measure) and clinically relevant health outcomes (including health-related quality of life [HRQOL] and adherence to recommended survivorship health behaviors). Univariate and multivariate analyses were used to assess demographic and disease-specific correlates of FT, and to assess the predictive value of FT on HRQOL and adherence to survivorship health behaviors. RESULTS: Approximately 18% of respondents noted FT levels associated with significant financial burden. In univariate analyses, after correcting for multiple comparisons, greater FT was associated with unpartnered status, non-retirement, and lower level of educational attainment. Greater FT was also significantly associated with HRQOL components of anxiety, fatigue, pain, physical functioning, and social functioning. FT was not significantly associated with any measured survivorship health behaviors. In multivariate analyses, FT was found to be a meaningful predictor of patient-reported anxiety, fatigue, physical functioning, and social functioning above and beyond theoretically and statistically relevant demographic characteristics. CONCLUSIONS: Although overall levels of FT were lower among cancer survivors in this sample, as compared with active treatment patients assessed in previous studies, financial burden continued to be a concern for a significant minority of cancer survivors and was associated with components of reduced HRQOL. Further research is needed to understand FT among underinsured survivors and those treated in community oncology settings. IMPLICATIONS FOR CANCER SURVIVORS: Incorporation of FT assessment into survivorship care planning could enhance clinical assessment of survivors' FT vulnerability, help address the dynamic and persistent challenges of survivorship, and help identify those most in need of intervention across the cancer care continuum.
PURPOSE: Fighting cancer is a costly battle, and understanding the relationship between patient-reported financial toxicity (FT) and health outcomes can help inform interventions for post-treatment cancer survivors. METHODS: Stages I-III solid tumor, insured US cancer survivors (N = 103) completed a survey addressing FT (as measured by the standardized COST measure) and clinically relevant health outcomes (including health-related quality of life [HRQOL] and adherence to recommended survivorship health behaviors). Univariate and multivariate analyses were used to assess demographic and disease-specific correlates of FT, and to assess the predictive value of FT on HRQOL and adherence to survivorship health behaviors. RESULTS: Approximately 18% of respondents noted FT levels associated with significant financial burden. In univariate analyses, after correcting for multiple comparisons, greater FT was associated with unpartnered status, non-retirement, and lower level of educational attainment. Greater FT was also significantly associated with HRQOL components of anxiety, fatigue, pain, physical functioning, and social functioning. FT was not significantly associated with any measured survivorship health behaviors. In multivariate analyses, FT was found to be a meaningful predictor of patient-reported anxiety, fatigue, physical functioning, and social functioning above and beyond theoretically and statistically relevant demographic characteristics. CONCLUSIONS: Although overall levels of FT were lower among cancer survivors in this sample, as compared with active treatment patients assessed in previous studies, financial burden continued to be a concern for a significant minority of cancer survivors and was associated with components of reduced HRQOL. Further research is needed to understand FT among underinsured survivors and those treated in community oncology settings. IMPLICATIONS FOR CANCER SURVIVORS: Incorporation of FT assessment into survivorship care planning could enhance clinical assessment of survivors' FT vulnerability, help address the dynamic and persistent challenges of survivorship, and help identify those most in need of intervention across the cancer care continuum.
Entities:
Keywords:
Cancer; Financial toxicity; Health-related quality of life; Patient-reported outcomes; Survivor; Survivorship health behaviors
Authors: Jonas A de Souza; Bonnie J Yap; Fay J Hlubocky; Kristen Wroblewski; Mark J Ratain; David Cella; Christopher K Daugherty Journal: Cancer Date: 2014-06-20 Impact factor: 6.860
Authors: Heidi A Hamann; Jamie S Ostroff; Emily G Marks; David E Gerber; Joan H Schiller; Simon J Craddock Lee Journal: Psychooncology Date: 2013-10-03 Impact factor: 3.894
Authors: Scott F Huntington; Brendan M Weiss; Dan T Vogl; Adam D Cohen; Alfred L Garfall; Patricia A Mangan; Jalpa A Doshi; Edward A Stadtmauer Journal: Lancet Haematol Date: 2015-09-17 Impact factor: 18.959
Authors: Ryan D Nipp; Hang Lee; Emily Gorton; Morgan Lichtenstein; Salome Kuchukhidze; Elyse Park; Bruce A Chabner; Beverly Moy Journal: Oncologist Date: 2019-04-15
Authors: Richard Huan Xu; Ling-Ling Wang; Ling-Ming Zhou; Eliza Lai-Yi Wong; Dong Wang Journal: Support Care Cancer Date: 2022-01-27 Impact factor: 3.603
Authors: Suji Udayakumar; Eden Solomon; Wanrudee Isaranuwatchai; Danielle L Rodin; Yoo-Joung Ko; Kelvin K W Chan; Ambica Parmar Journal: Support Care Cancer Date: 2022-03-23 Impact factor: 3.603